Irvine Scientific ships first products from plant in Tokyo

Published: 24-Aug-2011
Packaging Pharmaceutical

Facility produces animal component-free cell culture media

Irvine Scientific has shipped the first products from its industrial cell culture media production facility in Tokyo to customers in Japan and Asia.

The new facility, located in Saitama prefecture, manufactures animal component-free cell culture media in volume requirements ranging from research use to production of biopharmaceuticals and vaccines. The plant has been commissioned and validated as completely animal component free (ACF).

The new facility, which meets the highest quality cGMP standards, currently occupies 1,720m2 and replicates the production and processes used at the Irvine Scientific’s Santa Ana, CA, US manufacturing facility.

The Tokyo site has state-of-the-art formulation and packaging equipment, and uses continuous milling and blending equipment designed and built to Irvine Scientific specifications. There is room for expansion depending on customer demands.

The Tokyo facility capacity doubles Irvine Scientific’s current powder manufacturing capability at Santa Ana and will bring the total capacity at both sites to more than 1.2 million kilos a year.

Irvine Scientific, a member of JX Holdings group, is a designer, manufacturer and distributor of industrial cell culture, cytogenetic, assisted reproductive technology (ART) and specialist media products. It is a large-scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets.

See more

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Read more
Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant

Trending Articles

  1. The IND advantage: why early derisking is a strategic imperative for complex biologics As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
  2. Nestlé Health Science and IdB partner to bring VOWST to Europe Nestlé Health Science and IdB Holding have signed a licensing agreement to seek EMA approval for VOWST, the only FDA-approved oral live biotherapeutic for recurrent C. diff prevention
  3. Pfizer and Innovent Biologics strike $10.5bn oncology deal spanning 12 cancer programmes The global licensing and co-development agreement covers a pipeline of ADCs and multi-specific antibodies, combining Innovent's discovery engine with Pfizer's clinical and commercial scale
  4. ystral opens ATEX-compliant trial centre in Germany to expand customer process development capacity The new facility, based in Ballrechten-Dottingen, will be able to handle flammable and explosive media testing across pharma, coatings and food applications, with remote livestream access and in-house particle size and viscosity analysis
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Pharma supply chains face record drug shortages as geopolitical, cyber and quality risks converge A new Moody's report identifies four compounding risk factors driving pharmaceutical supply chain instability and warns that siloed risk management is leaving the sector dangerously exposed

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Design & Build

Fujifilm Irvine Scientific plans Netherlands manufacturing facility

Dry powder media, liquid media, and downstream bioprocessing liquids will all come out of this new plant
Ingredients

Irvine introduces NK cell expansion medium for immunotherapy and translational research applications

The first chemically defined, animal component-free cell culture medium for natural killer (NK) cells
Manufacturing

Fujifilm completes acquisition of Irvine Scientific Sales Company and IS Japan

With the acquisition of ISUS and ISJ, Fujifilm will now be able to provide a broad product portfolio from biopharmaceuticals to <i>in vitro</i> fertilisation and cell therapy
Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Packaging

SnapSlide single-handed prescription vial launches in US pharmacies targeting dexterity-impaired patients

The patented sliding closure eliminates the push-and-twist mechanism of conventional vials, maintaining child-resistance standards while improving medication access for patients with arthritis or limited hand strength
Subscribe now